PLT 012
Alternative Names: PLT-012Latest Information Update: 28 Aug 2025
At a glance
- Originator Pilatus Biosciences
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD36 antigen antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Immunological disorders; Liver cancer; Liver metastases; Solid tumours
Most Recent Events
- 13 Aug 2025 Pilatus Biosciences collaborates with Roche for atezolizumab
- 13 Aug 2025 Pilatus Biosciences plans a phase I first-in-human trial for Liver cancer (Combination therapy) in USA (Parenteral), in 2025
- 30 Apr 2025 Pharmacodynamics and adverse event data from a preclinical trial in Solid tumours released by Pilatus Biosciences